AlphaCognition, Inc. has two projects in its drug pipeline. ALPHA-1062 has completed two human clinical programs and is entering the final pivotal trial stage.  A regulatory pathway has been reviewed and commented on by the US FDA and we are progressing on that path.  Meetings with Japanese authorities will occur in the early part of 2020 and an approval pathway for Japan may be defined.  Meetings with European authorities were held and have provided advice for approval for ALPHA-1062.